LncRNA UCA1 in anti-cancer drug resistance

被引：134
|
作者：
Wang, Haohao [1 ,2 ]
Guan, Zhonghai [1 ]
He, Kuifeng [1 ,2 ]
Qian, Jiong [1 ]
Cao, Jiang [3 ]
Teng, Lisong [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Ctr Canc, Hangzhou, Zhejiang, Peoples R China
[2] Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Clin Res Ctr, Hangzhou, Zhejiang, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 38期
基金：
中国国家自然科学基金;
关键词：
long non-coding RNA; UCA1; chemoresistance; cancer; LONG NONCODING RNA; CARCINOMA-ASSOCIATED; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; ENHANCES TAMOXIFEN RESISTANCE; TYROSINE KINASE INHIBITORS; BREAST-CANCER; MULTIDRUG-RESISTANCE; POOR-PROGNOSIS; MOLECULAR-MECHANISMS;
D O I：
10.18632/oncotarget.18344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
引用
收藏
页码：64638 / 64650
页数：13
相关论文
共 50 条
  • [41] LncRNA—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p
    Zehua Bian
    Liugen Jin
    Jiwei Zhang
    Yuan Yin
    Chao Quan
    Yaling Hu
    Yuyang Feng
    Heyong Liu
    Bojian Fei
    Yong Mao
    Leyuan Zhou
    Xiaowei Qi
    Shenlin Huang
    Dong Hua
    Chungen Xing
    Zhaohui Huang
    Scientific Reports, 6
  • [42] Is there a place for the UCA1 test in bladder cancer detection?
    Milowich, D.
    Le Mercier, M.
    De Neve, N.
    Fossion, C.
    Sandras, F.
    Roumeguere, T.
    Decaestecker, C.
    Salmon, I.
    Rorive, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S202 - S202
  • [43] Correction to: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs
    Chao-Jie Wang
    Chun-Chao Zhu
    Jia Xu
    Ming Wang
    Wen-Yi Zhao
    Qiang Liu
    Gang Zhao
    Zi-Zhen Zhang
    Molecular Cancer, 20
  • [44] Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer
    Wang, Minghui
    Zhang, Zhijun
    Pan, Deng
    Xin, Zhigang
    Bu, Fan
    Zhang, Yue
    Tian, Qingwu
    Feng, Xiaodong
    BIOSCIENCE REPORTS, 2021, 41 (07)
  • [45] Serum-Based lncRNA ANRIL, TUG1, UCA1, and HIT Expressions in Breast Cancer Patients
    Alkhathami, Ali G.
    Hadi, Abdul
    Alfaifi, Mohammed
    Alshahrani, Mohammad Yahya
    Verma, Amit Kumar
    Beg, Mirza Masroor Ali
    DISEASE MARKERS, 2022, 2022
  • [46] Lncrna uca1 interacts directly with angiomotin to activate Hippo-YAP signaling in epithelial ovarian cancer
    Lin, Xianzhi
    Spindler, Tassja J.
    Gayther, Simon A.
    Lawrenson, Kate
    CANCER RESEARCH, 2018, 78 (13)
  • [47] LncRNA UCA1在肿瘤诊断中的研究进展
    王思宇
    王宇
    生命科学, 2022, 34 (07) : 806 - 814
  • [48] LncRNA UCA1 regulates proliferation, migration and invasion of cervical cancer cells by targeting miR-145
    Wei, H.
    Qiu, Y-Q
    Zeng, Q-S
    Wang, S-F
    Yi, C-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (07) : 3555 - 3564
  • [49] LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway
    Wang, Huizhi
    Ding, Yuntao
    He, Yuxin
    Yu, Zhengyue
    Zhou, Yujing
    Gong, Aihua
    Xu, Min
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2023, 748
  • [50] LncRNA UCA1 promotes tumorigenesis of breast cancer via targeting MiR-185-5p
    Zhang, Chao
    Hua, Yanmei
    Zhong, Xianfeng
    MINERVA MEDICA, 2022, 113 (05) : 889 - 890
12345